Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: JMarcus who wrote (720)	11/19/1999 7:29:00 AM
From: BRAVEHEART	Read Replies (1) \| Respond to of 1494

Hi Marc, No way. The current accumulation pattern is by your second tier group of investors. A more conservative group. One which waits till Big Pharma or a Major investor has taken a position. Someone who essentially evaluates potential & creates investor confidence. The recent $4 million was one third the company. That's a "MAJOR" position. Note the 300,000 share day. Right Institutional Investors. Next up should be the clinical trial results. More confidence. Then a Major Pharmaceutical Collaboration. More Confidence. Initiation of P-III trials. More Confidence. Relisting with NASDAQ. Even more confidence. With the right market conditions $6+ is not out of the question after these almost certain market events transpire. Of course this is my interpretation. But a lot of money is pouring in that general direction. So to answer your question...No...A spike is almost a certainty...say $1.5 above the then trading value. This is contingent on current market conditions. Also on the twist of the news. If data is coupled with a collaboration higher valuations are a certainty. Just clinical results might fizzel a bit more. Realize the results are expected. A "MAJOR" collaboration is not for the most part. Then again stocks are rallying that much on next to nothing. BEST WISHES Jeffrey